Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-α2b in metastatic melanoma
E. Bajetta, N. Cascinelli, Alberto Fusi(Charité - Universitätsmedizin Berlin), Sewa S. Legha(The University of Texas MD Anderson Cancer Center), Paola Queirolo, Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Antonio Daponte(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Maria Grazia Bernengo(University of Turin), M.R. Sertoli(National Cancer Research Institute), P. Nova(Sorbonne Université), Barbara Formisano(Fondazione IRCCS Istituto Nazionale dei Tumori), Paola Taveggia(National Cancer Research Institute)
Cited by 114
Related Papers
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
|The Lancet Oncology|2017|780
Inefficacy of Immediate Node Dissection in Stage 1 Melanoma of the Limbs
|New England Journal of Medicine|1977|667
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
|Journal of Clinical Oncology|2011|657